BTK Inhibitor: Novartis: No Liver Toxicity Seen to Date.

Published Date: 06 May 2023

Novartis expressed cautious optimism that its anti-inflammatory drug candidate, remibrutinib, might avoid the side effects that have plagued competing products in the same drug class by saying no signs of liver damage had yet been observed in trials testing the drug.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot